The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer
HL Matlung, K Szilagyi, NA Barclay… - Immunological …, 2017 - Wiley Online Library
Immune checkpoint inhibitors, including those targeting CTLA‐4/B7 and the PD‐1/PD‐L1
inhibitory pathways, are now available for clinical use in cancer patients, with other …
inhibitory pathways, are now available for clinical use in cancer patients, with other …
[HTML][HTML] Cancer immunotherapy targeting the CD47/SIRPα axis
K Weiskopf - European journal of cancer, 2017 - Elsevier
The success of cancer immunotherapy has generated tremendous interest in identifying new
immunotherapeutic targets. To date, the majority of therapies have focussed on stimulating …
immunotherapeutic targets. To date, the majority of therapies have focussed on stimulating …
Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy
AA Barkal, K Weiskopf, KS Kao, SR Gordon… - Nature …, 2018 - nature.com
Exciting progress in the field of cancer immunotherapy has renewed the urgency of the need
for basic studies of immunoregulation in both adaptive cell lineages and innate cell …
for basic studies of immunoregulation in both adaptive cell lineages and innate cell …
Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites
Neuroendocrine neoplasms (NENs) comprise well-differentiated neuroendocrine tumors
(NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Treatment options for …
(NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Treatment options for …
[HTML][HTML] The challenge of targeting cancer stem cells to halt metastasis
A Agliano, A Calvo, C Box - Seminars in Cancer Biology, 2017 - Elsevier
Despite a continuing debate about the existence of cancer stem cells (CSCs), recent
discoveries have provided further support for their existence and their roles in drug …
discoveries have provided further support for their existence and their roles in drug …
Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure–function
The macrophage checkpoint is an anti-phagocytic interaction between signal regulatory
protein alpha (SIRPα) on a macrophage and CD47 on all types of cells–ranging from blood …
protein alpha (SIRPα) on a macrophage and CD47 on all types of cells–ranging from blood …
Advances in therapeutic targeting of cancer stem cells within the tumor microenvironment: an updated review
Despite great strides being achieved in improving cancer patients' outcomes through better
therapies and combinatorial treatment, several hurdles still remain due to therapy …
therapies and combinatorial treatment, several hurdles still remain due to therapy …
Exosomal CD47 plays an essential role in immune evasion in ovarian cancer
A Shimizu, K Sawada, M Kobayashi… - Molecular Cancer …, 2021 - AACR
Ovarian cancer is largely diagnosed at advanced stages upon detection of multiple
peritoneal dissemination, resulting in poor outcomes. CD47 is overexpressed in tumors …
peritoneal dissemination, resulting in poor outcomes. CD47 is overexpressed in tumors …
CD73 regulates stemness and epithelial-mesenchymal transition in ovarian cancer-initiating cells
M Lupia, F Angiolini, G Bertalot, S Freddi… - Stem cell reports, 2018 - cell.com
Cancer-initiating cells (CICs) have been implicated in tumor development and
aggressiveness. In ovarian carcinoma (OC), CICs drive tumor formation, dissemination, and …
aggressiveness. In ovarian carcinoma (OC), CICs drive tumor formation, dissemination, and …
Pancreatic neuroendocrine tumors: molecular mechanisms and therapeutic targets
Simple Summary Pancreatic neuroendocrine tumors (pNETs) are rare, indolent cancers
whose causation is only partly understood. An increasing number of studies have uncovered …
whose causation is only partly understood. An increasing number of studies have uncovered …